FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, in particular to a new insulin analogue; it can be used in medicine. The invention makes it possible to obtain an insulin analogue, an amino acid sequence of which implies at least one modification of amino acids selected from a group consisting of the 16th amino acid of the B-chain, the 25th amino acid of the B-chain, the 14th amino acid of the A-chain and the 19th amino acid of the A-chain of native insulin. Such an analogue has reduced binding affinity relatively to insulin receptors, however, in comparison with native insulin, it has greater stability and increased in vivo lifetime.
EFFECT: invention can be applied in medical practice in the treatment of subjects suffering from diabetes.
21 cl, 4 tbl, 4 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| CONJUGATE OF LONG-ACTING PHYSIOLOGICALLY ACTIVE SUBSTANCE AND ITS USE | 2018 |
|
RU2773823C2 |
| PEPTIDE HAVING AMYLIN PROPERTIES (VERSIONS) AND USE THEREOF (VERSIONS) | 2005 |
|
RU2385878C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| COMPOSITION AND MICROSPHERE WITH CONTROLLED EXENDIN RELEASE AND METHOD OF OBTAINING MICROSPHERE | 2008 |
|
RU2463040C2 |
| METHOD FOR INHIBITING GLUCAGON | 2000 |
|
RU2247575C9 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
| PEPTIDE, PHARMACEUTICAL COMPOSITION (VERSIONS) AND MEDICATION | 2007 |
|
RU2492183C2 |
| INSULIN ANALOGUES CHARACTERIZED BY REDUCED AFFINITY OF BINDING TO INSULIN RECEPTORS | 2019 |
|
RU2816595C2 |
